UNASSIGNED: We conducted a systematic review and meta-analysis of preclinical studies published before 26 July 2023, identified in PubMed, Embase, and Scopus. Four independent reviewers extracted the data and assessed the risks of bias. The effects of U. tomentosa on inflammatory diseases and the inflammatory mediators involved were extracted from the studies. Standardized mean differences (SMD) and 95% confidence intervals (95%CI) of the outcomes were estimated. The meta-analyses were conducted using RevMan 5.4 (Cochrane Collaboration). This protocol was registered in PROSPERO (CRD42023450869).
UNASSIGNED: Twenty-four of 523 studies were included. U. tomentosa extracts decreased the cytokines interleukin (IL)-6 (SMD: -0.72, 95%CI: -1.15, -0.29, p = 0.001) and transcription factor nuclear factor kappa-B (NF-κB) (SMD: -1.19, 95%CI: -1.89, -0.48, p = 0.001). However, the extracts did not significantly alter IL-1 (SMD: -0.16, 95%CI: -0.87, +0.56, p = 0.67), IL-10 (SMD: -0.05, 95%CI:-0.35, 0.45, p = 0.80), or tumor necrosis factor-alpha (TNF-α) levels (SMD: 0.18, 95%CI: -0.25, 0.62, p = 0.41).
UNASSIGNED: Many extracts of stem bark, roots, and leaves of U. tomentosa, mostly aqueous and hydroethanolic, exhibited anti-inflammatory and/or immunomodulatory activities and low toxicity. The extracts decreased NF-κB and IL-6. These findings suggest that this species has the potential to treat inflammatory diseases in which these markers are increased, according to the ethnopharmacological use. These activities are not related to a specific class of compounds.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=450869, Identifier CRD42023450869.
■我们对2023年7月26日之前发表的临床前研究进行了系统评价和荟萃分析,Embase,还有Scopus.四名独立审稿人提取了数据并评估了偏见的风险。从研究中提取了绒毛膜下对炎性疾病的影响以及所涉及的炎症介质。估计结果的标准化平均差异(SMD)和95%置信区间(95CI)。荟萃分析使用RevMan5.4(CochraneCollaboration)进行。该协议在PROSPERO(CRD42023450869)中注册。
■纳入了523项研究中的24项。绒毛乳杆菌提取物降低细胞因子白细胞介素(IL)-6(SMD:-0.72,95CI:-1.15,-0.29,p=0.001)和转录因子核因子κB(NF-κB)(SMD:-1.19,95CI:-1.89,-0.48,p=0.001)。然而,提取物没有显著改变IL-1(SMD:-0.16,95CI:-0.87,+0.56,p=0.67),IL-10(SMD:-0.05,95CI:-0.35,0.45,p=0.80),或肿瘤坏死因子-α(TNF-α)水平(SMD:0.18,95CI:-0.25,0.62,p=0.41)。
■许多茎皮提取物,根,和毛霉的叶子,主要是水性和乙醇,表现出抗炎和/或免疫调节活性和低毒性。提取物降低NF-κB和IL-6。这些发现表明,该物种具有治疗这些标志物增加的炎症性疾病的潜力,根据民族药理学使用。这些活性与特定类别的化合物无关。
系统审查注册:https://www。crd.约克。AC.uk/prospro/display_record.php?RecordID=450869,标识符CRD42023450869。